Kiyatec
29 articles about Kiyatec
-
Kiyatec Appoints Eric Perreault as New CEO to Lead Strategic Expansion
1/4/2024
Kiyatec, a leading biotechnology company specializing in 3D cell culture technology, is pleased to announce the promotion of Eric Perreault to the position of chief executive officer.
-
Kiyatec strengthens its leadership position with the addition of Mark Capone, former CEO of Myriad Genetics, as Strategic Advisor
11/21/2023
Kiyatec is pleased to announce that Mark Capone, former CEO of Myriad Genetics, has joined its team as a strategic advisor.
-
Kiyatec Appoints Eric Perreault to President and Appoints Tessa DesRochers, PhD, Chief Scientific Officer to Vice President of Pre-Clinical Services
8/1/2023
Kiyatec, a leading biotechnology company specializing in 3D cell culture technologies, is pleased to announce the appointment of Eric Perreault to the position of President.
-
Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-PredictTM
5/30/2023
Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-Predict TM.
-
Kiyatec Announces Investment from Leading Brain Cancer Venture Philanthropy Funds
5/18/2023
Kiyatec, Inc., the leader in functional precision oncology, announced a new investment from the venture philanthropy arms of two leading brain tumor patient organizations.
-
Kiyatec to present two posters highlighting the company’s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL
4/11/2023
Kiyatec, the leader in clinically correlated, published functional precision oncology technology, today announced that two abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting to be held in Orlando, Florida from April 14 – 19, 2023.
-
Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform
12/12/2022
Kiyatec Inc. announced a closing of its Series C funding round totaling US$18 million from new and existing investors.
-
Kiyatec to Sponsor and Exhibit at the Virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022
9/7/2022
Kiyatec announced the company is sponsoring and exhibiting at the virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022.
-
KIYATEC to Present New Clinical Correlation Data at American Association for Cancer Research
3/14/2022
KIYATEC today announced that six abstracts were accepted for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
-
KIYATEC Announces Addition of Chief Commercial Officer Stacy Chick to Executive Team
9/21/2021
The functional precision oncology company KIYATEC, Inc. announced today the addition of Chief Commercial Officer, Stacy Chick, to their Executive Team.
-
KIYATEC Marks Glioblastoma Awareness Day by Initiating Use of 3D Predict™ Glioma Test Outside of Clinical Study
7/21/2021
Functional precision oncology innovator KIYATEC announced today that it is initiating use of the 3D Predict™ Glioma test outside of its 3D-PREDICT clinical study
-
KIYATEC Clinical Study Data Shows Test Accurately Predicts Brain Cancer Patient Response to Standard Drug Therapy Prior to Treatment
6/17/2021
KIYATEC, Inc . announced today the publication of new peer-reviewed data that establishes clinically meaningful prediction of patient-specific responses to standard of care therapy, prior to treatment, in newly diagnosed glioblastoma (GBM).
-
University of Arkansas for Medical Sciences Joins KIYATEC Clinical Study of Test to Predict Pre-Treatment, Patient-Specific Response to Ovarian Cancer Drugs
6/25/2020
KIYATEC, Inc. today announced that the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) has joined the growing roster of institutions participating in its 3D-PREDICT clinical study to validate the company’s test as a patient-specific predictor of response to recommended drug therapies for patients with ovarian cancer. “Ovarian cancer patients and clinicians do
-
Cancer Diagnostics Innovator KIYATEC Advancing Functional Ex Vivo 3D Cell Culture Models that Reveal Response Dynamics to Immuno-Oncology Drugs
6/22/2020
Cancer Diagnostics Innovator KIYATEC Advancing Functional Ex Vivo 3D Cell Culture Models that Reveal Response Dynamics to Immuno-Oncology Drugs Key evidence to be presented at AACR 2020 GREENVILLE, S.C.--( BUSINESS WIRE )-- KIYATEC, Inc. today announced that it will present data at the 2020 American Association for Cancer Research (AACR) Annual Meeting, June 22-24, revealing how its 3D cell culture models characterize ex vivo tumor response and
-
BioSpace Movers & Shakers, May 8
5/8/2020
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Cancer Diagnostics Innovator KIYATEC Adds Clinical and Reimbursement Experience to Board as Clinical Testing Validation Progresses
5/4/2020
KIYATEC, Inc. today announced the appointment of Bruce Nash, MD, MBA, to its Board of Directors. Dr. Nash brings over 30 years of executive-level healthcare experience in the managed care, hospital and medical group practice settings. Currently, he serves as Chief Physician Executive and Senior Vice President at Blue Cross Blue Shield of Massachusetts, one of the nation’s leading health insurance plans. During his caree
-
VA Portland Health Care System Joins KIYATEC Clinical Study of Test to Predict Pre-Treatment, Patient-Specific Response to Glioblastoma Drugs
3/2/2020
KIYATEC, Inc. today announced that VA Portland Health Care System (VAPORHCS) has joined the growing roster of institutions participating in its 3D-PREDICT clinical study to validate the company’s test as a patient-specific predictor of response to cancer therapies for patients with glioblastoma, an aggressive form of brain cancer.
-
KIYATEC Secures Investment from Life Sciences Venture Fund Esperante to Fuel Clinical Assay Validation Efforts
1/8/2020
KIYATEC, Inc. announced that it has secured an investment from life sciences venture investment company Esperante.
-
KIYATEC To Present Immuno-Oncology Response Characterization at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/5/2019
KIYATEC, Inc. today announced that it will present data characterizing in vitro response to checkpoint inhibitors in solid tumors, a capability that addresses an important need in preclinical development of immuno-oncology (I/O) therapies.
-
KIYATEC Announces Addition of Capital Health as Clinical Site in Trial to Predict GBM Patient-Specific Response to Cancer Drugs Prior to Treatment
8/13/2019
KIYATEC, Inc. today announced that Capital Health has joined its U.S. clinical trial, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer therapies in glioblastoma (GBM) and anaplastic astrocytoma (AA) patients.